Nu-Med Plus, Inc. is an early-stage medical device developer focused on cost-effective nitric oxide delivery systems with patented technology. Despite initial lab setup and prototype development, the company has yet to generate revenue and struggles with substantial operating losses and a critically low cash runway of about two months. Nu-Med faces significant regulatory challenges requiring costly FDA approvals, which have stalled progress given the absence of sufficient capital. Competition from established firms with FDA-cleared products also limits market entry prospects. Key milestones include securing financing, advancing device testing, and initiating submission for regulatory clearance, all currently uncertain.